Cynata Therapeutics Ltd has released a press release.
Appendix 4E & Financial Statements
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Cymerus MSCs improve cardiac recovery in preclinical study
- June 2018 Quarterly Report
- Cynata Enters Development Partnership with RCSI
- Product Development Program Update & Investor Presentation
- Positive 28-day Clinical Trial Data in Cohort B
Later from Cynata Therapeutics
- Cynata GvHD Trial Meets all Safety & Efficacy Endpoints
- Cynata Advances to Official Meeting with Japanese PMDA
- Cynata MSCs Ameliorate CRS in Preclinical Study
- MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical Studies
- Engineered Cymerus™ MSCs Demonstrate Anti-Cancer Effects in Preclinical Studies
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics